Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00420186 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT00420186 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 37 participants.
The verdict
NCT00420186, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this clinical research is to assess the safety and tolerability of BMS-690514 when given in combination with paclitaxel and carboplatin. Paclitaxel and carboplatin will be administered on a standard regimen every 3 weeks at standard doses. BMS-690514 will be given in the interval at escalating doses until the maximum tolerated dose (MTD) is identified. An additional cohort of subjects will be treated with BMS-690514 at the MTD in combination with Paclitaxel and carboplatin
Interventions
- DRUG BMS-690514
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00420186
The ClinicalTrials.gov registry entry for NCT00420186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-690514 is the first listed.
NCT00420186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00420186 about?
NCT00420186 is a clinical study titled "A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin". The purpose of this clinical research is to assess the safety and tolerability of BMS-690514 when given in combination with paclitaxel and carboplatin. Paclitaxel and carboplatin will be administered on a standard regimen every 3 weeks at standard doses. BMS-690514 will be given in the interval at e...
What is the current status of trial NCT00420186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2007-10. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00420186?
The interventions under investigation include: BMS-690514 (DRUG).
Who is sponsoring clinical trial NCT00420186?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.